Atopic Dermatitis: key endpoint results by drug

The key endpoints of Atopic Dermatitis trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Atopic Dermatitis page.

EASI-75

EASI-75 in Atopic Dermatitis: 20 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
abrocitinib39.7%11.8%+27.9100 mg · wk 12 · n 156NCT03349060 Phase 3, primary
astegolimab27.3%18.8%+8.5wk 16 · n 33NCT03747575 Phase 2, secondary
baricitinib31.5%17.2%+14.34 mg · wk 16 · n 92NCT03428100 Phase 3, primary
brepocitinib32.4%35.1%−2.70.1% Cream QD · wk 6 · n 37NCT03903822 Phase 2, secondary
crisaborole46.4%27.6%+18.82% twice a day · wk 4.14 · n 260NCT04360187 Phase 3, secondary
dupilumab62.6%29.6%+33300 mg Q2W · wk 16 · n 107NCT02755649 Phase 3, primary
etrasimod38.3%26.1%+12.22 mg · wk 12 · n 47NCT04162769 Phase 2, secondary
lebrikizumab51.2%13.4%+37.8250 mg Q2W · wk 16 · n 123NCT04760314 Phase 3, primary
nemolizumab43.5%29%+14.530 mg · wk 16 · n 620NCT03985943 Phase 3, primary
Nitrosomonas eutropha (B244)27.7%15.8%+11.9O.D. 5.0 · wk 4 · n 166NCT04490109 Phase 2, secondary
Rademikibart58.6%22.6%+36300mg Q2W · wk 16 · n 219NCT05017480 Phase 2, secondary
rilzabrutinib29.6%29%+0.6wk 16 · n 27NCT05018806 Phase 2, secondary
risankizumab21.7%11.8%+9.9300 mg · wk 16 · n 69NCT03706040 Phase 2, primary
Roflumilast (Zoryve)43.2%22%+21.20.15% cream · wk 4 · n 433NCT04773587 Phase 3, secondary
spesolimab0.2%0.1%+0.1600 mg intravenous every 4 weeks · wk 16 · n 33NCT03822832 Phase 2, secondary
Tapinarof55.8%22.9%+32.9wk 8 · n 270NCT05014568 Phase 3, secondary
tezepelumab24.4%19.8%+4.6280 mg · wk 12 · n 55NCT02525094 Phase 2, secondary
tozorakimab10.5%7.1%+3.4Dose 1 · wk 16 · n 19NCT04212169 Phase 2, secondary
tralokinumab25%12.7%+12.3300 mg Q2W · wk 16 · n 601NCT03131648 Phase 3, primary
upadacitinib60.1%13.3%+46.815 mg QD · wk 16 · n 276NCT03607422 Phase 3, primary

Drugs checked with no result here: 36 not reported, 13 trial running, 6 not posted.

IGA 0/1 with 2-point improvement

IGA 0/1 with 2-point improvement in Atopic Dermatitis: 7 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
abrocitinib27.8%6.3%+21.5100mg QD · wk 12 · n 56NCT02780167 Phase 2, primary
baricitinib21.7%9.7%+124 mg · wk 16 · n 92NCT03428100 Phase 3, secondary
lebrikizumab33.4%6.1%+27.3250 mg Q2W · wk 16 · n 123NCT04760314 Phase 3, primary
nemolizumab33.3%12.3%+2130 mg · wk 16 · n 57NCT03100344 Phase 2, secondary
spesolimab9.1%0%+9.1600 mg intravenous every 4 weeks · wk 16 · n 33NCT03822832 Phase 2, secondary
tezepelumab19.3%12.8%+6.5280 mg · wk 12 · n 55NCT02525094 Phase 2, secondary
tralokinumab11.6%11.8%−0.2wk 12 · n 50NCT02347176 Phase 2, primary

Drugs checked with no result here: 43 not reported, 17 trial running, 8 not posted.

EASI-90

EASI-90 in Atopic Dermatitis: 14 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
abrocitinib28.5%14.6% (Dupilumab)—200 mg QD · wk 4 · n 354NCT04345367 Phase 3, primary
baricitinib16%4.8%+11.24 mg · wk 16 · n 125NCT03334396 Phase 3, secondary
dupilumab35.7%7.6%+28.1300 mg q2w · wk 16 · n 224NCT02277743 Phase 3, secondary
etrasimod14.9%10.9%+42 mg · wk 12 · n 47NCT04162769 Phase 2, secondary
lebrikizumab34.3%9.8%+24.5250 mg Q2W · wk 16 · n 123NCT04760314 Phase 3, secondary
nemolizumab33.3%8.8%+24.530 mg · wk 16 · n 57NCT03100344 Phase 2, secondary
Nitrosomonas eutropha (B244)15.1%5.8%+9.3O.D. 5.0 · wk 4 · n 166NCT04490109 Phase 2, secondary
Rademikibart33.4%6.4%+27300mg Q2W · wk 16 · n 219NCT05017480 Phase 2, secondary
risankizumab8.7%2.9%+5.8300 mg · wk 16 · n 69NCT03706040 Phase 2, secondary
Roflumilast (Zoryve)17.4%17.8%−0.40.05% · wk 4 · n 46NCT03916081 Phase 2, secondary
Tapinarof29.8%6.1%+23.7wk 8 · n 270NCT05014568 Phase 3, secondary
tozorakimab0%0%±0Dose 1 · wk 16 · n 19NCT04212169 Phase 2, secondary
tralokinumab14.5%4.1%+10.4300 mg Q2W · wk 16 · n 601NCT03131648 Phase 3, secondary
upadacitinib42.4%5.4%+3715 mg QD · wk 16 · n 276NCT03607422 Phase 3, secondary

Drugs checked with no result here: 41 not reported, 14 trial running, 6 not posted.

EASI, % change

EASI, % change in Atopic Dermatitis: 20 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
abrocitinib-60%-28.6%−31.4100 mg · wk 12 · n 158NCT03575871 Phase 3, secondary
apremilast-31.6%-11.0%−20.640 mg · wk 12 · n 63NCT02087943 Phase 2, primary
astegolimab-51.5%-58.2%+6.8wk 16 · n 33NCT03747575 Phase 2, primary
baricitinib-59.4%-34.8%−24.54 mg · wk 16 · n 70NCT03334396 Phase 3, secondary
brepocitinib-58.3%-44.4%−13.90.1% Cream QD · wk 6 · n 37NCT03903822 Phase 2, primary
crisaborole-59.9%-42.8%−17.12% twice a day · wk 4 · n 260NCT04360187 Phase 3, primary
dupilumab0.1%21.7%−21.6300 mg Q2W/QW · wk 36 · n 169NCT02395133 Phase 3, primary
etrasimod-57.2%-48.4%−8.82 mg · wk 12 · n 47NCT04162769 Phase 2, primary
lebrikizumab-64.2%-25.3%−39250 mg Q2W · wk 16 · n 123NCT04760314 Phase 3, secondary
nemolizumab-73.4%-58.4%−1530 mg · wk 24 · n 57NCT03100344 Phase 2, primary
Rademikibart-57.6%-39.7%−17.9150 Q2W · wk 16 · n 57NCT04444752 Phase 2, primary
rilzabrutinib-53.6%-43.3%−10.2wk 16 · n 24NCT05018806 Phase 2, primary
risankizumab-45.4%-28.5%−16.8300 mg · wk 16 · n 43NCT03706040 Phase 2, secondary
Roflumilast (Zoryve)-69.4%-55.8%−13.50.05% · wk 4 · n 46NCT03916081 Phase 2, secondary
secukinumab-5.0%5.3%−10.2wk 16 · n 14NCT02594098 Phase 2, secondary
spesolimab-37.9%-12.3%−25.6600 mg intravenous every 4 weeks · wk 16 · n 28NCT03822832 Phase 2, primary
tezepelumab-25.3%-11.3%−14700 mg IV · wk 16.14 · n 9NCT00757042 Phase 1, secondary
tralokinumab-77.8%-73.5%−4.3wk 16 · n 53NCT04587453 Phase 3, secondary
upadacitinib-74.1%-34.5%−39.615 mg QD · wk 16 · n 246NCT03607422 Phase 3, secondary
ustekinumab-39.4%-37.5%−1.990 mg · wk 12 · n 28NCT01945086 Phase 2, primary

Drugs checked with no result here: 35 not reported, 14 trial running, 6 not posted.

  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 75 approved or late-stage drugs with a featured trial in Atopic Dermatitis were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.